Which has better earnings and valuation, IKT or OLMA?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A

Is IKT or OLMA more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Olema Pharmaceuticals N/A -46.00% -41.22%

Which has preferable earnings and valuation, IKT or ORIC?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A

Is IKT or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Oric Pharmaceuticals N/A -35.33% -33.31%

Which has better earnings and valuation, CGEM or IKT?

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A

Is CGEM or IKT more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Inhibikase Therapeutics N/A -41.31% -38.98%

Inhibikase Therapeutics (IKT) Competitors

$1.88 +0.01 (+0.27%)

As of 10:10 AM Eastern

Compare

IKT vs. ETON, OLMA, TBPH, ORIC, and CGEM

Should you buy Inhibikase Therapeutics stock or one of its competitors? MarketBeat compares Inhibikase Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inhibikase Therapeutics include Eton Pharmaceuticals (ETON), Olema Pharmaceuticals (OLMA), Theravance Biopharma (TBPH), Oric Pharmaceuticals (ORIC), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry.

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

In the previous week, Eton Pharmaceuticals had 3 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 0 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 beat Eton Pharmaceuticals' score of -0.05 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eton Pharmaceuticals	Neutral
Inhibikase Therapeutics	Neutral

Eton Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Eton Pharmaceuticals currently has a consensus target price of $41.00, indicating a potential upside of 22.73%. Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 184.81%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

Inhibikase Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

Eton Pharmaceuticals has higher revenue and earnings than Inhibikase Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	11.44	-$4.60M	-$0.07	N/A
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A

Summary

Eton Pharmaceuticals beats Inhibikase Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Olema Pharmaceuticals?

Inhibikase Therapeutics (NASDAQ:IKT) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Inhibikase Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market.

Inhibikase Therapeutics presently has a consensus target price of $5.40, indicating a potential upside of 184.81%. Olema Pharmaceuticals has a consensus target price of $44.10, indicating a potential upside of 308.14%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Inhibikase Therapeutics' return on equity of -41.31% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 1 mentions for Olema Pharmaceuticals and 0 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 beat Olema Pharmaceuticals' score of -1.57 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
Olema Pharmaceuticals	Very Negative

Summary

Inhibikase Therapeutics beats Olema Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Theravance Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Theravance Biopharma has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.23	$105.89M	$2.20	7.80
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A

Theravance Biopharma has a net margin of 104.34% compared to Inhibikase Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

Theravance Biopharma presently has a consensus price target of $21.40, indicating a potential upside of 24.69%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 184.81%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

In the previous week, Theravance Biopharma had 3 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 0 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.05 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Theravance Biopharma	Neutral
Inhibikase Therapeutics	Neutral

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Theravance Biopharma beats Inhibikase Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Oric Pharmaceuticals?

Inhibikase Therapeutics (NASDAQ:IKT) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Oric Pharmaceuticals' return on equity of -35.33% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Inhibikase Therapeutics presently has a consensus price target of $5.40, indicating a potential upside of 184.81%. Oric Pharmaceuticals has a consensus price target of $18.92, indicating a potential upside of 105.28%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 1 mentions for Oric Pharmaceuticals and 0 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.00 equaled Oric Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
Oric Pharmaceuticals	Neutral

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Inhibikase Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Summary

Inhibikase Therapeutics beats Oric Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Cullinan Therapeutics currently has a consensus target price of $32.00, suggesting a potential upside of 78.82%. Inhibikase Therapeutics has a consensus target price of $5.40, suggesting a potential upside of 184.81%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cullinan Therapeutics had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 2 mentions for Cullinan Therapeutics and 0 mentions for Inhibikase Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.27 beat Inhibikase Therapeutics' score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cullinan Therapeutics	Neutral
Inhibikase Therapeutics	Neutral

Inhibikase Therapeutics' return on equity of -41.31% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

Summary

Inhibikase Therapeutics beats Cullinan Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IKT vs. The Competition

Export

Metric	Inhibikase Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$250.20M	$461.63M	$4.34B	$12.30B
Dividend Yield	N/A	N/A	10.93%	5.83%
P/E Ratio	-4.41	N/A	22.07	23.99
Price / Sales	N/A	66.25	151.48	118.14
Price / Cash	N/A	N/A	40.77	54.51
Price / Book	0.82	2.73	18.62	6.50
Net Income	-$48.26M	-$81.71M	$115.37M	$336.88M
7 Day Performance	12.86%	4.05%	-0.47%	-0.16%
1 Month Performance	12.19%	-1.78%	-1.84%	0.76%
1 Year Performance	N/A	N/A	11.97%	28.49%

Inhibikase Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
IKT Inhibikase Therapeutics	1.6458 of 5 stars	$1.90 +1.4%	$5.40 +184.8%	N/A	$250.20M	N/A	N/A	6
ETON Eton Pharmaceuticals	4.0556 of 5 stars	$32.15 +1.8%	$41.00 +27.5%	+147.9%	$865.33M	$79.95M	N/A	20
OLMA Olema Pharmaceuticals	1.9106 of 5 stars	$9.88 +0.1%	$44.10 +346.4%	+151.3%	$862.12M	N/A	N/A	70
TBPH Theravance Biopharma	2.5271 of 5 stars	$16.32 -1.9%	$21.83 +33.8%	+60.5%	$857.84M	$107.46M	7.42	110
ORIC Oric Pharmaceuticals	1.8753 of 5 stars	$8.40 +1.6%	$18.92 +125.2%	-10.9%	$856.09M	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IKT) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibikase Therapeutics (IKT) Competitors

IKT vs. ETON, OLMA, TBPH, ORIC, and CGEM

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Summary

How does Inhibikase Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Inhibikase Therapeutics compare to Theravance Biopharma?

Summary

How does Inhibikase Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Inhibikase Therapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibikase Therapeutics (IKT) Competitors

IKT vs. ETON, OLMA, TBPH, ORIC, and CGEM

How does Inhibikase Therapeutics compare to Eton Pharmaceuticals?

Does the media prefer ETON or IKT?

Which has more risk and volatility, ETON or IKT?

Do institutionals & insiders have more ownership in ETON or IKT?

Do analysts rate ETON or IKT?

Is ETON or IKT more profitable?

Which has preferable valuation and earnings, ETON or IKT?

Summary

How does Inhibikase Therapeutics compare to Olema Pharmaceuticals?

Which has better earnings and valuation, IKT or OLMA?

Which has more volatility & risk, IKT or OLMA?

Do analysts recommend IKT or OLMA?

Is IKT or OLMA more profitable?

Do insiders and institutionals have more ownership in IKT or OLMA?

Does the media favor IKT or OLMA?

Summary

How does Inhibikase Therapeutics compare to Theravance Biopharma?

Which has more volatility & risk, TBPH or IKT?

Which has preferable valuation and earnings, TBPH or IKT?

Is TBPH or IKT more profitable?

Do analysts rate TBPH or IKT?

Does the media refer more to TBPH or IKT?

Do institutionals and insiders believe in TBPH or IKT?

Summary

How does Inhibikase Therapeutics compare to Oric Pharmaceuticals?

Is IKT or ORIC more profitable?

Do analysts rate IKT or ORIC?

Do insiders & institutionals have more ownership in IKT or ORIC?

Does the media favor IKT or ORIC?

Which has preferable earnings and valuation, IKT or ORIC?

Which has more risk & volatility, IKT or ORIC?

Summary

How does Inhibikase Therapeutics compare to Cullinan Therapeutics?

Which has more volatility and risk, CGEM or IKT?

Do analysts recommend CGEM or IKT?

Which has better earnings and valuation, CGEM or IKT?

Do insiders & institutionals hold more shares of CGEM or IKT?

Does the media prefer CGEM or IKT?

Is CGEM or IKT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools